Fundraising Fox
/Companies
Sign in

Arpeggio Bio

YC S19

Boulder, US · Founded 2018 · Delaware corporation · 20 employees · 16 known investors

Find your way into Arpeggio Bio

Sign up to see every warm intro you have to Arpeggio Bio

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Arpeggio Bio team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Arpeggio Bio develops pharmaceutical drugs that target transcription factors using artificial intelligence and RNA-sequencing technology, with lead programs in development for melanoma treatment and rare disease applications.

Also known as Arpeggio Biosciences, Inc. · Arpeggio Biosciences

BiotechHealthtechGenomicsDrug discoveryUnited States of AmericaAmerica / Canada

Founders & leadership· Y Combinator alumni (S19)

Arpeggio Bio was founded in 2018 by Joey Azofeifa.

JAJoey Azofeifa
Joey AzofeifaFounder & CEO2019–2026Founder of Arpeggio Bio, which develops pharmaceutical drugs targeting transcription factors using artificial intelligence and RNA-sequencing technology for melanoma and rare disease applications.30 Under 30 2020
LNLaura Norris
Laura NorrisCOO & Co-founder
TR
Timothy ReadExecutive
EM
Eric MartinChief Scientific Officer2022–2023

Board

AM
Amit MehtaBoard director

Investors · 16

Fifty Yearslisted by Fifty YearsSan Francisco · $250K – $2M

How we know: Fifty Years's portfolio page · the VCSheet dataset · Y Combinator's founder network · Not right? Tell us

FundersClublisted by FundersClubSan Francisco · $290K

How we know: FundersClub's portfolio page · Y Combinator's founder network · Not right? Tell us

Tau Ventureslisted by Tau VenturesPalo Alto · $500K

How we know: the VCSheet dataset · Y Combinator's founder network · Not right? Tell us

venBio Partnerslisted by venBio PartnersSan Francisco

How we know: the VCSheet dataset · Not right? Tell us

Y Combinatorlisted by Y CombinatorSan Francisco · $500K

How we know: the Y Combinator directory · open dataset · 5k.vc investor directory · Not right? Tell us

Alamo AngelsreportedSan Antonio

How we know: a partner's Signal profile · Not right? Tell us

BoxOne VenturesreportedMontréal · $500K

How we know: the VCSheet dataset · Not right? Tell us

Builders VCreportedSan Francisco

How we know: a partner's Signal profile · Y Combinator's founder network · Not right? Tell us

Formic VenturesreportedSan Francisco

How we know: Y Combinator's founder network · Not right? Tell us

Khosla VenturesreportedMenlo Park · $100K – $20M

How we know: Y Combinator's founder network · Not right? Tell us

TechU VenturesreportedCedarhurst

How we know: Y Combinator's founder network · Not right? Tell us

Tencent HoldingsreportedShenzhen

How we know: Y Combinator's founder network · Not right? Tell us

venBio Global StrategicinferredSan Francisco

How we know: board seat on SEC Form D · Not right? Tell us

Venture Investment AssociatesreportedPeapack

How we know: Y Combinator's founder network · Not right? Tell us

Westlake Village BioPartnersreportedLos Angeles · $100K – $5Mvia David Allison · board

How we know: board seat on SEC Form D · Y Combinator's founder network · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$46.4M disclosed across 5 rounds · 2019–2025

▶$20MraisedNov 2025 · 12 investors · Other Technology
Rule 506(b)
Officers, directors & promoters on the filing
  • Timothy ReadExecutive Officer
  • Laura NorrisExecutive Officer
  • David AllisonDirector
  • Joseph G. AzofeifaExecutive Officer, Director
  • Mira ChaurushiyaDirector
  • Samuel KintzDirector
  • Aaron RoystonDirector
Offering amount
$35.3M
Amount sold
$20M
First sale
Nov 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$4MraisedMar 2025 · 14 investors · Other Technology
Rule 506(b)
Officers, directors & promoters on the filing
  • Amit MehtaDirector
  • Timothy ReadExecutive Officer, Director
  • Laura NorrisExecutive Officer, Director
  • Joseph G. AzofeifaExecutive Officer, Director
Offering amount
$4.6M
Amount sold
$4M
First sale
Mar 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$20.2MraisedSep 2022 · 28 investors · Other Technology
Rule 506(b)
Officers, directors & promoters on the filing
  • Amit MehtaDirector
  • Laura NorrisExecutive Officer, Director
  • Joseph G. AzofeifaExecutive Officer, Director
  • Timothy ReadExecutive Officer, Director
  • Eric MartinExecutive Officer
Offering amount
$20.3M
Amount sold
$20.2M
First sale
Aug 2022
Incorporated
Corporation, Delaware, 2017
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2MraisedSep 2019 · 5 investors · Other Technology
Rule 506(b)
Officers, directors & promoters on the filing
  • Joseph G. AzofeifaExecutive Officer, Director, Promoter
  • Timothy ReadDirector, Promoter
  • Joe McMahonDirector
  • Daniel WeaverPromoter
  • Robin D. Dowell-DeenPromoter
  • Laura NorrisExecutive Officer
Offering amount
$3M
Amount sold
$2M
First sale
Aug 2019
Incorporated
Corporation, Colorado, 2017
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$125KraisedAug 2019 · 1 investors · Other Technology
Rule 506(b)
Officers, directors & promoters on the filing
  • Laura NorrisExecutive Officer
  • Robin D. Dowell-DeenPromoter
  • Daniel WeaverPromoter
  • Timothy ReadDirector, Promoter
  • Joseph G. AzofeifaExecutive Officer, Director, Promoter
  • Joe McMahonDirector
Offering amount
$500K
Amount sold
$125K
First sale
Aug 2019
Incorporated
Corporation, Colorado, 2017
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 10

Talus BioTalus develops a proprietary platform that measures and modulates the regulome—the body's gene expression control system—in native cellular contexts. The company designs AI-driven compounds and uses functional proteomics to enable drug discovery for transcription factors and regulatory proteins implicated in oncology, rare disease, and immune dysfunction.
BioAge LabsBIOAGE develops therapies targeting the molecular pathways that drive aging to increase healthspan and address age-related chronic diseases. The company uses data-driven approaches and bioinformatics to identify and develop its pipeline of aging-focused therapeutics.
Anto BiosciencesAnto is an AI research lab developing foundation models for microbial communities to enable precision medicine by computationally modeling how the microbiome affects individual drug response. The company serves pharmaceutical and clinical research by combining AI with genomic and microbiome data.
Sequence BioSequence Bio discovers genetic causes of disease within Newfoundland and Labrador's founder population to develop breakthrough treatments, diagnostics, and preventions. The company focuses on translational biology and genetics research for patients globally.
Aro BiotherapeuticsAro Biotherapeutics develops tissue-targeted genetic medicines using a proprietary protein technology called Centyrins. The company builds a wholly-owned pipeline of Centyrin-based therapeutic candidates and partners with industry to enable tissue-specific targeting of therapeutics across a range of diseases.
Felix BiotechnologyFelix Biotechnology develops a digital platform for designing viruses intended to combat antimicrobial resistance.
BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Ochre BioOchre Bio develops RNA therapeutics and drug discovery platforms targeting liver disease, combining proprietary human liver datasets with AI-driven causal prediction and human tissue validation models. The company aims to address the global shortage of liver transplants by developing new treatment options for liver fibrosis and cirrhosis.
Primrose BioPrimrose Bio develops high-efficiency production systems for innovative and complex biologics, using advanced protein expression and enzyme engineering technologies deployed across commercially proven platforms. The company serves pharmaceutical developers and contract manufacturers in the biopharmaceutical industry.
BridgebioBridgeBio develops treatments for genetic conditions and cancers using a decentralized hub-and-spoke model, where autonomous teams focus on specific diseases or drug candidates while a central hub provides clinical, regulatory, and commercial support. The company partners with academic institutions to advance early-stage research toward late-stage clinical trials.

Companies working in the same space as Arpeggio Bio.

Legal entities · 1

corporate structure
Arpeggio Biosciences, Inc.

Frequently asked questions

What does Arpeggio Bio do?
Arpeggio Bio develops pharmaceutical drugs that target transcription factors using artificial intelligence and RNA-sequencing technology, with lead programs in development for melanoma treatment and rare disease applications.
Who founded Arpeggio Bio?
Arpeggio Bio was founded by Joey Azofeifa in 2018.
Who are Arpeggio Bio's investors?
Arpeggio Bio's investors include ATEM Capital Fund, Fifty Years, FundersClub, Tau Ventures, venBio Partners, Y Combinator, Alamo Angels, BoxOne Ventures and 8 more.
How much funding has Arpeggio Bio raised?
Arpeggio Bio has disclosed $46.4M raised across 5 rounds.
Where is Arpeggio Bio headquartered?
Arpeggio Bio is headquartered in Boulder, US.